Salicylic acid protects against chronic l-DOPA-induced 6-OHDA generation in experimental model of parkinsonism

Brain Research

Volumn 1344, Issue , 2010, Pages 192-199

  Borah, Anupom ^a,b   Mohanakumar, Kochupurackal P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b ASSAM UNIVERSITY   (India)

Author keywords

Dopamine oxidation product; Dopamine quinones; Hydroxyl radical; l DOPA toxicity; Median forebrain bundle; MPTP; Neurodegeneration; Neuroprotection; Parkinson's disease; Reactive oxygen species

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ASCORBIC ACID; DOPAMINE; FERROUS ION; LEVODOPA; OXIDOPAMINE; SALICYLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; EXPERIMENTAL MOUSE; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDIAL FOREBRAIN BUNDLE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; HOMOVANILLIC ACID; LEVODOPA; MALE; MEDIAL FOREBRAIN BUNDLE; MICE; MICE, INBRED BALB C; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; SALICYLIC ACIDS;

MUS; PARKINSONIA;

EID: 77954087418     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.05.010     Document Type: Article

References (56)

1. Andrew R., Watson D.G., Best S.A., Midgley J.M., Wenlong H., and Petty R.K. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem. Res. 18 (1993) 1175-1177
2. Aubin N., Curet O., Deffois A., and Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J. Neurochem. 71 (1998) 1635-1642
3. Borah A., and Mohanakumar K.P. Long-term l-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell. Mol. Neurobiol. 27 (2007) 985-996
4. Borah A., and Mohanakumar K.P. Long term l-DOPA treatment causes production of 6-OHDA in the mouse striatum: involvement of hydroxyl radical. Ann. Neurosci. 16 (2009) 160-165
5. Borah A., and Mohanakumar K.P. Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. J. Pineal Res. 47 (2009) 293-300
6. Borah A., and Mohanakumar K.P. l-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation. Neurochem. Int. 56 (2010) 357-362
7. +: protection by acetylsalicylic acid (aspirin). Parkinsonism Relat. Disord. 8 (2002) 407-411
8. Cenci M.A. l-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment. Parkinsonism Relat. Disord. 13 (2007) S263-267
9. Chan G.C., Hinds T.R., Impey S., and Storm D.R. Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J. Neurosci. 18 (1998) 5322-5332
10. Chen L., Ding Y., Cagniard B., Van Laar A.D., Mortimer A., Chi W., Hastings T.G., Kang U.J., and Zhuang X. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J. Neurosci. 28 (2008) 425-433
11. Chiueh C.C., Wu R.M., Mohanakumar K.P., Sternberger L.M., Krishna G., Obata T., and Murphy D.L. In vivo generation of hydroxyl radicals and MPTP-induced dopaminergic toxicity in the basal ganglia. Ann. NY Acad. Sci. 738 (1994) 25-36
12. Curtius H.C., Wolfensberger M., Steinmann B., Redweik U., and Siegfried J. Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. J. Chromatogr. 99 (1974) 529-540
13. Dabbeni-Sala F., Di Santo S., Franceschini D., Skaper S.D., and Giusti P. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J. 15 (2001) 164-170
14. Dexter D.T., Wells F.R., Agid F., Agid Y., Lees A.J., Jenner P., and Marsden C.D. Increased nigral iron content in postmortem parkinsonian brain. Lancet 2 (1987) 1219-1220
15. Evans J., and Cohen G. Catecholamine uptake inhibitors elevate 6-hydroxydopamine in brain after administration of 6-hydroxydopa. Eur. J. Pharmacol. 232 (1993) 241-245
16. Ferger B., Teismann P., Earl C.D., Kuschinsky K., and Oertel W.H. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 360 (1999) 256-261
17. Filloux F., and Townsend J.J. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp. Neurol. 119 (1993) 79-88
18. Fox S.H., Chuang R., and Brotchie J.M. Parkinson's disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy. Prog. Brain Res. 172 (2008) 479-494
19. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14 (1978) 633-643
20. Grilli M., Pizzi M., Memo M., and Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 274 (1996) 1383-1385
21. Hastings T.G., Lewis D.A., and Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl Acad. Sci. USA 93 (1996) 1956-1961
22. Henze C., Earl C., Sautter J., Schmidt N., Themann C., Hartmann A., and Oertel W.H. Reactive oxidative and nitrogen species in the nigrostriatal system following striatal 6-hydroxydopamine lesion in rats. Brain Res. 1052 (2005) 97-104
23. Ishida Y., Hashiguchi H., Todaka K., Ishizuka Y., and Mitsuyama Y. Repeated administration of high dose levodopa enhances hydroxyl radical production in the rat striatum denervated with 6-hydroxydopamine. Neurosci. Lett. 290 (2000) 33-36
24. Jenner P.G., and Brin M.F. Levodopa neurotoxicity: experimental studies versus clinical relevance. Neurology 50 (1998) S39-43
25. Karoum F., Chrapusta S.J., Egan M.F., and Wyatt R.J. Absence of 6-hydroxydopamine in the rat brain after treatment with stimulants and other dopaminergic agents: a mass fragmentographic study. J. Neurochem. 61 (1993) 1369-1375
26. Kataoka M., Tonooka K., Ando T., Imai K., and Aimoto T. Hydroxyl radical scavenging activity of nonsteroidal anti-inflammatory drugs. Free Radic. Res. 27 (1997) 419-427
27. Kuo C.H., Yonehara N., Hata F., and Yoshida H. Subcellular distribution of ascorbic acid in rat brain. Jpn J. Pharmacol. 28 (1978) 789-791
28. Leret M.L., San Millan J.A., Fabre E., Gredilla R., and Barja G. Deprenyl protects from MPTP-induced Parkinson-like syndrome and glutathione oxidation in rat striatum. Toxicology 170 (2002) 165-171
29. Liao P.C., Kuo Y.M., Chang Y.C., Lin C., Cherng C.F., and Yu L. Striatal formation of 6-hydroxydopamine in mice treated with pargyline, pyrogallol and methamphetamine. J. Neural Transm. 110 (2003) 487-494
30. Maharaj D.S., Saravanan K.S., Maharaj H., Mohanakumar K.P., and Daya S. Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Neurochem. Int. 44 (2004) 355-360
31. Maharaj H., Sukhdev Maharaj D., Scheepers M., Mokokong R., and Daya S. l-DOPA administration enhances 6-hydroxydopamine generation. Brain Res. 1063 (2005) 180-186
32. Mefford I.N., Oke A.F., and Adams R.N. Regional distribution of ascorbate in human brain. Brain Res. 212 (1981) 223-226
33. Mohanakumar K.P., and Muralikrishnan D. Neurochemical mechanisms underlying neuroprotective actions of bromocriptine, salicylate, d- and l-deprenyl in neurodegeneration caused by MPTP. In: Collins M.A., and Storch A. (Eds). Neurotoxic Factors in Parkinson's Disease and Related Disorders (2000), Kluwer Academic/Plenum Press, New York 289-294
34. Mohanakumar K.P., De Bartolomeis A., Wu R.M., Yeh K.J., Sternberger L.M., Peng S.Y., Murphy D.L., and Chiueh C.C. Ferrous-citrate complex and nigral degeneration: evidence for free radical formation and lipid peroxidation. Ann. NY Acad. Sci. 738 (1994) 392-399
35. Mohanakumar K.P., Muralikrishnan D., and Thomas B. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity. Brain Res. 864 (2000) 281-290
36. Mohanakumar K.P., Thomas B., Sharma S.M., Muralikrishnan D., Chowdhury R., and Chiueh C.C. Nitric oxide: an antioxidant and neuroprotector. Ann. NY Acad. Sci. 962 (2002) 389-401
37. Mosharov E.V., Larsen K.E., Kanter E., Phillips K.A., Wilson K., Schmitz Y., Krantz D.E., Kobayashi K., Edwards R.H., and Sulzer D. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62 (2009) 218-229
38. Pandey M., Borah A., Varghese M., Barman P.K., Mohanakumar K.P., and Usha R. Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats. Neurochem. Int. 55 (2009) 431-437
39. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1998), Academic Press, San Diego
40. Rollema H., De Vries J.B., Westerink B.H., Van Putten F.M., and Horn A.S. Failure to detect 6-hydroxydopamine in rat striatum after the dopamine releasing drugs dexamphetamine, methylamphetamine and MPTP. Eur. J. Pharmacol. 132 (1986) 65-69
41. Sairam K., Saravanan K.S., Banerjee R., and Mohanakumar K.P. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res. 966 (2003) 245-252
42. Saravanan K.S., Sindhu K.M., Senthilkumar K.S., and Mohanakumar K.P. l-Deprenyl protects against rotenone-induced, oxidative stress mediated dopaminergic neurodegeneration in rats. Neurochem. Int. 49 (2006) 28-40
43. Schapira A.H., Emre M., Jenner P., and Poewe W. Levodopa in the treatment of Parkinson's disease. Eur. J. Neurol. 16 (2009) 982-989
44. Seiden L.S., and Vosmer G. Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methyl amphetamine. Pharmacol. Biochem. Behav. 21 (1984) 29-31
45. Senthilkumar K.S., Saravanan K.S., Chandra G., Sindhu K.M., Jayakrishnan A., and Mohanakumar K.P. Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism. Behav. Brain Res. 184 (2007) 11-18
46. Sharma R., McMillan C.R., Tenn C.C., and Niles L.P. Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease. Brain Res. 1068 (2006) 230-236
47. Slivka A., and Cohen G. Hydroxyl radical attack on dopamine. J. Biol. Chem. 260 (1985) 15466-15472
48. Soto-Otero R., Méndez-Alvarez E., Sánchez-Iglesias S., Zubkov F.I., Voskressensky L.G., Varlamov A.V., de Candia M., and Altomare C. Inhibition of 6-hydroxydopamine-induced oxidative damage by 4,5-dihydro-3H-2-benzazepine N-oxides. Biochem. Pharmacol. 75 (2008) 1526-1537
49. Spencer J.P., Jenner A., Butler J., Aruoma O.I., Dexter D.T., Jenner P., and Halliwell B. Evaluation of the pro-oxidant and antioxidant actions of l-DOPA and dopamine in vitro: implications for Parkinson's disease. Free Radic. Res. 24 (1996) 95-105
50. Teismann P., and Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39 (2001) 167-174
51. Thomas B., Muralikrishnan D., and Mohanakumar K.P. In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in mice. Brain Res. 852 (2000) 221-224
52. Tse D.C., Mccreery R.L., and Adams R.N. Potential oxidative pathways of brain catecholamines. J. Med. Chem. 19 (1976) 37-40
53. Ungerstedt U., and Arbuthnott G.W. Quantitative recording of rotational behaviour in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 24 (1970) 485-493
54. Vane J.R., and Botting R.M. Anti-inflammatory drugs and their mechanism of action. Inflamm. Res. 47 (1998) S78-S87
55. Xu X.-M., Sansores-Garcia L., Chen X.-M., Matijevic-Aleksic N., Du M., and Wu K.K. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc. Natl Acad. Sci. USA 96 (1999) 5292-5297
56. Yang C.S., Tsai P.J., Lin N.N., Liu L., and Kuo J.S. Elevated extracellular glutamate levels increased the formation of hydroxyl radical in the striatum of anesthetized rat. Free Radic. Biol. Med. 19 (1995) 453-459